Citanest is one of 85 small molecule programs targeting Prostate Carcinoma. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
230 competitors in Cesarean Section
Marcaine
Pitocin
Naropin
Neo-Synephrine
Proamatine
Duragesic
Versed
Catapres
Xylocaine
Ancef
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
CITANEST
NDA NDA014763
Jan 1, 1982
CITANEST PLAIN DENTAL
NDA NDA021382
Sources
Details